An efficient protocol for synthesis of 3,3'-diindolylmethanes using recyclable Fe-pillared interlayered clay (Fe-PILC) catalyst under aqueous medium has been developed. All synthesized 3,3'-diindolylmethanes showed promising antileishmanial activity against Leishmania donovani promastigotes as well as axenic amastigotes. Structure-activity relationship analysis revealed that nitroaryl substituted diindolylmethanes showed potent antileishmanial activity. The 4-nitrophenyl linked 3,3'-diindolylmethane 8g was found to be the most potent antileishmanial analog showing IC50 values of 7.88 and 8.37 μM against both L. donovani promastigotes and amastigotes, respectively. Further, a pharmacophore based QSAR model was established to understand the crucial molecular features of 3,3'-diindolylmethanes essential for potent antileishmanial activity. These compounds also exhibited promising antifungal activity against Cryptococcus neoformans, wherein fluorophenyl substituted 3,3'-diindolylmethanes were found to be most potent antifungal agents. Developed synthetic protocol will be useful for economical and eco-friendly synthesis of potent antileishmanial and antifungal 3,3'-diindolylmethane class of compounds.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674182 | PMC |
| http://dx.doi.org/10.1016/j.ejmech.2013.02.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In vitro and in silico approaches manifest the anti-leishmanial activity of wild edible mushroom .
In Silico Pharmacol
December 2024
Laboratory of Cell and Molecular Biology, Department of Botany, Centre of Advanced Study, University of Calcutta, 35 Ballygunge Circular Road, Kolkata, 700019 India.
Visceral Leishmaniasis, caused by is the second most deadly parasitic disease, causing over 65,000 deaths annually. Synthetic drugs available in the market, to combat this disease, have numerous side effects. In this backdrop, we aim to find safer antileishmanial alternatives with minimal side effects from mushrooms, which harbour various secondary metabolites with promising efficacy.
View Article and Find Full Text PDFSynthesis and in vitro leishmanicidal activity of novel N-arylspermidine derivatives.
Bioorg Chem
December 2024
Universidad de Buenos Aires, CONICET, Cátedra de Química Orgánica II, Departamento de Ciencias Químicas, Facultad de Farmacia y Bioquímica, Junín 956, 1113 Buenos Aires, Argentina. Electronic address:
This work describes the synthesis and biological evaluation of hitherto unknown N-arylspermidine derivatives 3. Compounds 3 were efficiently prepared from cyclic amidines through a novel synthetic approach comprising alkylation with ω-halonitriles followed by reduction. The cyclic N-arylamidine directs the alkylation to the unsubstituted nitrogen and also provides the N-benzyl group present in the triamine after simultaneous reduction of the resulting quaternary salt 2 and the cyano group.
View Article and Find Full Text PDFGenome alteration of Leishmania orientalis under Amphotericin B inhibiting conditions.
PLoS Negl Trop Dis
December 2024
Department of Genetics, Faculty of Science, Kasetsart University, Bangkok, Thailand.
Article Synopsis
- Amphotericin B (AmB) is a strong antifungal and antiparasitic drug that kills leishmanial parasites by disrupting their cell membranes, making it important to study its effects on parasites like Leishmania orientalis to understand potential drug resistance.
- This study involved exposing a specific Leishmania orientalis strain to AmB and analyzing genetic changes through sequencing methods, focusing on single nucleotide polymorphisms (SNPs) and gene expression changes.
- The results indicated no significant chromosomal alterations post-treatment, but a higher incidence of SNPs in the control group, along with the downregulation of key genes, suggesting complex regulatory mechanisms might contribute to AmB resistance in this strain.
Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.
ChemMedChem
December 2024
Nantes Université: Nantes Universite, Chimie Thérapeutique UR 1155 - IICiMed, IRS2 22 Boulevard Bénoni Goullin, 44200, Nantes, FRANCE.
Our research group previously discovered CTN1122, an imidazo[1,2-a]pyrazine compound with promising antileishmanial activity against intramacrophage amastigotes of Leishmania major and L. donovani strains. CTN1122 effectively targets Leishmania casein kinase 1 (L-CK1.
View Article and Find Full Text PDFPhytochemical profiling and evaluation of compounds targeting Leishmania N-myristoyltransferase: molecular docking, drug-likeness, and toxicity analyses.
Front Chem
November 2024
NanoStruc Research Group, Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt.
Background: has long been recognized for its therapeutic properties against various diseases. Among these is leishmaniasis, a parasitic infection that remains a global health challenge. Targeting Leishmania N-myristoyltransferase (NMT), a crucial enzyme for parasite survival, represents a promising therapeutic approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!